

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 7,923,217 B2
APPLICATION NO. : 10/652372
DATED : April 12, 2011
INVENTOR(S) : Enno Adema

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Delete the Title page and insert the Title page attached.

Signed and Sealed this
Twenty-seventh Day of September, 2011

A handwritten signature in black ink that reads "David J. Kappos". The signature is written in a cursive, flowing style with a large initial "D" and a stylized "K".

David J. Kappos
Director of the United States Patent and Trademark Office

(12) **United States Patent**
Adema

(10) **Patent No.:** **US 7,923,217 B2**
(45) **Date of Patent:** **Apr. 12, 2011**

(54) **SPECIFICITY IN THE DETERMINATION OF ANTITHROMBIN**

(75) Inventor: **Enno Adema, Heidelberg (DE)**

(73) Assignee: **Roche Diagnostics Operations, Inc., Indianapolis, IN (US)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 792 days.

(21) Appl. No.: **10/652,372**

(22) Filed: **Aug. 29, 2003**

(65) **Prior Publication Data**

US 2004/0043428 A1 Mar. 4, 2004

(30) **Foreign Application Priority Data**

Aug. 29, 2002 (DE) 102 39 821

(51) **Int. Cl.**

C12Q 1/46 (2006.01)

G01N 33/557 (2006.01)

C12N 15/15 (2006.01)

(52) **U.S. Cl.** **435/13; 436/517; 530/393**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,219,497 A * 8/1980 Plattner et al. 548/542
4,314,987 A * 2/1982 Morris et al. 436/508
4,883,751 A * 11/1989 Gitel et al. 435/7.92
5,118,790 A * 6/1992 Winant et al. 530/324
5,308,755 A * 5/1994 Nesheim et al. 435/7.4
5,320,945 A 6/1994 Dessauer et al.
5,693,641 A 12/1997 Buckman et al.
5,721,214 A 2/1998 Marlowe et al.
5,783,421 A 7/1998 Zeelon et al.
5,891,647 A 4/1999 Lormeau et al.
6,051,434 A * 4/2000 Exner 436/69
6,068,979 A * 5/2000 Akhavan-Tafti 435/6

FOREIGN PATENT DOCUMENTS

EP 0 041 366 A1 * 12/1991
JP 1017549 1/1989
JP 06094713 8/1994
WO EP 0 391 433 10/1990
WO EP 0 657 547 A1 6/1995
WO WO 96/40679 12/1996
WO WO 97/46523 12/1997
WO EP 0 927 767 A2 7/1999

OTHER PUBLICATIONS

Merriam-Webster's Online Dictionary, definition for the term "excess", retrieved from <http://www.merriam-webster.com/dictionary/excess> [1] on Oct. 18, 2008.*

Or Philo et al. "Comparison of antithrombin III assays using biological and chromogenic substrates" Br J Haematol. Jan. 1982;50(1):147-56.*

Topper, M., et al., *Enzyme-linked immunosorbent assay for thrombin-antithrombin III complexes in horses*; AJVR, 57(4):427-431 (1996).
Ruzzenente, O., et al., *Use of Purified Dermatan Sulfate for heparin Cofactor II (HCII) Assay*; Thrombosis Research; 65:281-287 (1992).
Pelzer, H., et al., *Determination of Human thrombin-Antithrombin II Complex in Plasma with an Enzyme-Linked Immunosorbent Assay*; Thrombosis and Haemostasis, 59(1):101-106 (1988).

Demers, C., et al., *An Antithrombin III Assay Based on Factor Xa Inhibition Provides a More Reliable Test to Identify Congenital Antithrombin III Deficiency Than an Assay Based on Thrombin Inhibition*; Thrombosis and Haemostasis; 69(3):231-235 (1993).

Hickey, et al. *Clinical evaluation of a new FXa-based Antithrombin assay on Sysmex® CA-1500 System*, 2008 GTI Congress (Congress of Gesellschaft Für Thrombose-und-Hämostaseforschung, held Feb. 20-23, 2008, Wiesbaden, Germany).

II. Stormorken, *New Methods for the Analysis of Coagulation Using Chromogenic Substrates; Studies on Antithrombin III Using Chromozym TH*, Proceedings of the Symposium of the Deutsche Gesellschaft Für Klinische Chemie, 119-121 (1976).

Odegard, et al. *Automated Antithrombin III Assay with a Centrifugal Analyser*, Haemostasis, 7:202-209 (1978).

Fareed, et al. *Current status of methodologies for antithrombin III and heparin with the advent of peptide chromogenic substrates*, Chromogenic Peptide Substrates, 183-191 (1979).

Abildgaard, et al. *Antithrombin (Heparin Cofactor) Assay with "New" Chromogenic Substrates (S-2238-Chromozym TH)*, Thrombosis Research, 11:549-553 (1977).

Ostrem, et al. *Discovery of a Novel, Potent, and Specific Family of Factor Xa Inhibitors via Combinatorial Chemistry*, Biochemistry, 37:1053-1059 (1998).

Lill, et al., *Methods of Enzymatic Analysis*, published in Bergmeyer, Methods in Enzymatic Analysis, 3rd Edition, Verlag Chemie, 5:441-448 (1986).

Witt, et al., *Neu Methoden der Gerinnungsanalyse mit chromagenen Substraten*, J. Clin. Chem. Clin. Biochem, 15:239-244 (1977) (concise explanation in specification, paragraph [0003]).

* cited by examiner

Primary Examiner — Gailene R Gabel

Assistant Examiner — Christine Foster

(74) *Attorney, Agent, or Firm* — McDonnell Boehnen Hulbert & Berghoff LLP

(57) **ABSTRACT**

Methods and reagents for determining antithrombin III (AT) in body fluids by adding an AT binding partner to the sample and determining the free AT binding partner.

10 Claims, No Drawings